

Rutgers Cancer Institute of New Jersey
Reporting Date: 03/31/2023
Program Area: Clinical Investigations and Precision Therapeutics
Data Table 2A – Active Funded Projects

Peer-Reviewed Research

PI	Specific Funding Source	Project Number	Project Start Date	Project End Date	Project Title	Annual Project Direct Costs	Cancer- Relevant Annual Project DC	Program Code	Program Percent	Annual Program Direct Costs
Baker T	NIDA	1UG3DA054787-01A1	9/30/2022	8/31/2024	RECOVERY OF REWARD FUNCTION IN NICOTINE USE DISORDER USING A COMBINATION OF ROBOTICS, ELECTROPHYSIOLOGY, AND TMS	\$242,501	\$242,501	04	50	\$121,251
Beaulieu A	NHLBI	7R01HL139818-05	1/1/2019	12/31/2023	BIRC5 AS A REGULATOR OF NK CELL DEVELOPMENT AND IMMUNE FUNCTION	\$225,000	\$225,000	04	100	\$225,000
Berger A	ECOG	CINJ Protocol #091909	1/22/1998	1/21/2099	EA6174: A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma	\$18,217	\$18,217	04	100	\$18,217
Cole P Sands S (MSKCC)	NCI	7R01CA220568-05	9/17/2018	8/31/2023	IDENTIFYING CHILDREN WITH SUBCLINICAL NEUROCOGNITIVE DECLINE AND SUSCEPTIBILITY TO OXIDATIVE DAMAGE DURING THE EARLY MONTHS OF THERAPY FOR ALL	\$546,312	\$546,312	04	100	\$546,312
Cole P Sussman E (Albert Einstein College of Med)	NCI Albert Einstein College of Med	5R01CA240360-03	3/1/2020	2/28/2025	CHARACTERIZATION OF BRAIN DYSFUNCTION DURING DEVELOPMENT IN SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA	\$139,255	\$139,255	04	100	\$139,255
Deek M	DoD	W81XWH-22-1-0579	7/1/2022	6/30/2024	UNDERSTANDING THE ROLE OF P53 IN THE DEVELOPMENT AND PROGRESSION OF OLIGOMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCER	\$388,454	\$388,454	04	100	\$388,454
Drachtman R	COG	CINJ Protocol #111007	9/30/2000	12/28/2099	CINJ PROTOCOL #111007	\$3,846	\$3,846	04	100	\$3,846
Drachtman R	COG	CINJ Protocol #111602	9/30/2000	12/28/2099	AAML1531: RISK-STRATIFIED THERAPY FOR ACUTE MYELOID LEUKEMIA IN DOWN SYNDROME.	\$962	\$962	04	100	\$962
Drachtman R	COG	CINJ Protocol #111702	9/30/2000	12/28/2099	CINJ PROTOCOL #111702	\$962	\$962	04	100	\$962
Drachtman R	COG	CINJ Protocol #111804	9/30/2000	12/28/2099	CINJ PROTOCOL #111804	\$2,692	\$2,692	04	100	\$2,692
Drachtman R	COG	CINJ Protocol #11706-H	9/30/2000	12/28/2099	CINJ PROTOCOL #11706-H	\$962	\$962	04	100	\$962
Drachtman R	ECOG	Project ID 6772	1/22/1998	4/21/2099	VARIOUS ECOG PROTOCOLS	\$57,950	\$57,950	04	100	\$57,950
Drachtman R	COG	7293	9/30/2000	9/29/2099	CHILDREN ONCOLOGY GROUP (VARIOUS)	\$18,423	\$18,423	04	100	\$18,423
Drachtman R	COG Children's Hospital of Philadelphia	CINJ Protocol #111104	7/1/2013	6/30/2099	PHASE III TRIAL FOR PT WITH DE NOVO AML USING BORTEZOMIB AND SORAFENIB	\$100	\$100	04	100	\$100
Drachtman R	COG	CINJ Protocol #111917	1/7/2020	1/6/2025	COG AALL1931/JZP458-201: An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coli-Derived Asparaginases	\$274,933	\$274,933	04	100	\$274,933
Drachtman R	COG	CINJ Protocol #112003	7/2/2020	7/1/2025	COG AAML1921: A Phase I/II Study of Bosutinib in Pediatric Patients with Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia	\$5,417	\$5,417	04	100	\$5,417
Drachtman R	COG	CINJ Protocol #111916	1/24/2021	1/23/2025	Childrens Oncology Group: ADVL1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors	\$0	\$0	04	100	\$0
Drachtman R	COG	CINJ Protocol #111914	10/15/2020	10/14/2025	ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma.	\$4,587	\$4,587	04	100	\$4,587
Drachtman R	COG	CINJ Protocol #111806	9/30/2000	9/29/2099	AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) (Childrens Oncology Group)	\$43,577	\$43,577	04	100	\$43,577
Drachtman R	COG	CINJ Protocol #112008	9/30/2000	9/29/2099	Childrens Oncology Group AAML1831 A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations	\$0	\$0	04	100	\$0
Drachtman R	COG	CINJ Protocol #111801	3/21/2018	3/31/2023	ADVL1722: A Phase 2, Multicenter, Open-Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)	\$18,250	\$18,250	04	100	\$18,250
Drachtman R Pollock B (Children's Hospital of Philadelphia)	NCI Children's Hospital of Philadelphia	5UG1CA189955-07	8/1/2014	7/31/2025	COG NCORP RESEARCH BASE	\$833	\$833	04	100	\$833
Einstein M Sparano J (Icahn School of Med. at Mount Sinai)	NCI Icahn School of Med. at Mount Sinai	7UM1CA121947-15	9/1/2019	8/31/2027	AIDS MALIGNANCY CONSORTIUM (AMC) - ANCHOR STUDY: ANAL CANCER/HSIL OUTCOMES RESEARCH STUDY	\$203,000	\$203,000	04	100	\$203,000

Einstein M Wilkin T (Weill Medical Coll of Cornell U.)	NCI Weill Medical Coll of Cornell U.	5U54CA242639-03	9/20/2019	7/31/2024	PARTNERSHIP FOR PREVENTION OF HPV-ASSOCIATED CANCERS IN PEOPLE LIVING WITH HIV: BRAZIL, MEXICO, AND PUERTO RICO	\$15,307	\$15,307	04	100	\$15,307
Evens A Parsons S (Tufts Medical Center)	NCI Tufts Medical Center	1R01CA262265-01A1	3/1/2022	2/28/2027	MODELING MULTI-SOURCE DATA IN HODGKIN LYMPHOMA	\$68,441	\$68,441	04	100	\$68,441
Evens A Zebrack B (U. of Michigan at Ann Arbor)	NCI U. of Michigan at Ann Arbor	1R01CA261752-01	9/1/2021	8/31/2026	SOCIAL GENOMIC MECHANISMS OF HEALTH DISPARITIES AMONG ADOLESCENT AND YOUNG ADULT (AYA) CANCER SURVIVORS	\$9,230	\$9,230	04	100	\$9,230
Foran D Saltz J (SUNY Stony Brook)	NCI SUNY Stony Brook	5UH3CA225021-05	4/1/2018	3/31/2024	METHODS AND TOOLS FOR INTEGRATING PATHOMICS DATA INTO CANCER REGISTRIES	\$125,803	\$125,803	04	100	\$125,803
Ganesan S	ECOG	CINJ Protocol #171701- Z1C	1/22/1998	1/21/2099	MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD- 0332991) in Patients with Tumors with CDK4 or CDK6 Amplification.	\$150	\$150	04	100	\$150
Ganesan S	ECOG	CINJ Protocol #171701- Z1G	1/22/1998	1/21/2099	EAY131-Z1G MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and Any PTEN Sequencing Result	\$1,000	\$1,000	04	100	\$1,000
Ganesan S Lattime E White F	NCI	5R01CA243547-03	12/1/2019	11/30/2024	IMPACT OF MUTATION BURDEN ON CANCER GROWTH AND THE IMMUNE LANDSCAPE	\$405,038	\$405,038	04	33	\$133,663
Ganesan S Liotta L (George Mason U.)	DoD George Mason U.	W81XWH-21-1-0044	2/1/2021	1/31/2024	HER2 PHOSPHORYLATION AND DIMERIZATION WITH EGFR PREDICT NEOADJUVANT HER2+ PCR FOR PERSONALIZED (ESCALATION OR DE-ESCALATION) BREAST CANCER THERAPY	\$85,031	\$85,031	04	100	\$85,031
Hinrichs C	NCI	2R00CA195682-02A1	3/31/2023	3/30/2028	THE LANDSCAPE OF TUMOR INTRINSIC GENETIC RESISTANCE TO T CELL THERAPY	\$499,000	\$499,000	04	50	\$249,500
Hou P	AACR	920002	7/1/2022	6/30/2025	ANTI-KRAS THERAPY RESISTANCE AND PANCREATIC TUMOR IMMUNE MICROENVIRONMENT	\$100,000	\$100,000	04	50	\$50,000
Howell R	NCI	7R01CA245139-04	2/15/2020	1/31/2025	MIRDCELL VERSION 3	\$224,175	\$224,175	04	100	\$224,175
Jabbour S	ECOG	CINJ Protocol #032013	1/22/1998	1/21/2099	EA5181: Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC	\$10,800	\$10,800	04	100	\$10,800
Jabbour S	ECOG	CINJ Protocol #071819	1/22/1998	1/21/2099	ECOG EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer.	\$14,400	\$14,400	04	100	\$14,400
Jabbour S	NCI	1R50CA275877-01	3/31/2023	3/31/2028	DR. SALMA JABBOUR'S NCI RESEARCH SPECIALIST (CLINICIAN SCIENTIST) AWARD (R50)	\$124,958	\$124,958	04	100	\$124,958
Jabbour S Siu L (University Health Network)	NCI University Health Network	3UM1CA186644-06	4/7/2014	2/28/2026	NORTH AMERICAN STAR CONSORTIUM	\$89,427	\$89,427	04	100	\$89,427
Langenfeld J	NCI	5R01CA225830-05	7/6/2018	6/20/2023	DEVELOPING BONE MORPHOGENETIC RECEPTOR II INHIBITORS FOR THE TREATMENT OF CANCER	\$224,175	\$224,175	04	100	\$224,175
Langenfeld J	NCI	3R01CA225830-05S1	7/1/2022	6/30/2023	DETERMINING THE MECHANISMS BY WHICH BONE MORPHOGENETIC PROTEIN INHIBITION PROMOTES SURVIVAL/NEUROGENESIS AND TO TRIGGER AMPK HYPERACTIVATION THAT INCLUDES NEURONAL AND CANCER DEATH CELL (SUPPLEMENT)	\$249,144	\$249,144	04	100	\$249,144
Langenfeld J	NCI	3R01CA225830-05S2	7/1/2022	6/30/2023	DEVELOPING BONE MORPHOGENETIC RECEPTOR II INHIBITORS FOR THE TREATMENT OF CANCER (SUPPLEMENT)	\$128,329	\$128,329	04	100	\$128,329
Libutti S Zamboni W (UNC Chapel Hill)	NCI UNC Chapel Hill	5R01CA247652-02	4/1/2021	3/31/2026	MINIBEAM RADIATION THERAPY ENHANCED DELIVERY OF NANOPARTICLE ANTICANCER AGENTS TO PANCREATIC CANCER TUMORS	\$78,341	\$78,341	04	50	\$39,171
Moghe P Pierce M	NIBIB	5R01EB018378-08	4/15/2014	5/31/2023	RARE EARTH NANOPROBES FOR OPTICAL IMAGING AND DISEASE TRACKING	\$434,109	\$434,109	04	50	\$217,055
Moghe P Pierce M	NIBIB	3R01EB018378-08S1	9/12/2022	5/31/2023	RARE EARTH NANOPROBES FOR OPTICAL IMAGING AND DISEASE TRACKING (C3I) (SUPPLEMENT)	\$98,579	\$98,579	04	50	\$49,290
Omene C	ECOG	CINJ Protocol #042004	1/22/1998	1/21/2099	EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients who Achieve a Pathologic Complete Response.	\$24,717	\$24,717	04	100	\$24,717
Panettieri R Libutti S Pasqualini R Pasqualini R	NHLBI/NCATS/NIAMS/ NINR/NIAAA/NIAD	7U01HL150852-04	9/23/2019	8/31/2023	RUTGERS OPTIMIZES INNOVATION (ROI) PROGRAM	\$636,942	\$318,471	04	50	\$159,236
Arap W Brinker C (UNM) Cristini V (UT)	NCI	5R01CA226537-05	8/1/2018	7/31/2023	A TARGETED NANOMEDICINE PROTOTYPE AGAINST ENZALUTAMIDE- RESISTANT PROSTATE CANCER	\$537,486	\$537,486	04	50	\$268,743
Pasqualini R Arap W Libutti S	NCI	7R01CA240516-04	3/15/2020	2/28/2025	DESIGNING A TRANSCRIPTOME-BASED, TARGETED THERANOSTIC PLATFORM FOR PROSTATE CANCER	\$224,175	\$224,175	04	50	\$112,088
Sarkar D	NCI	5R01CA208632-05	6/1/2017	5/31/2023	TARGETING THE OPIOIDERGIC AND ADRENERGIC SYSTEMS TO CONTROL BREAST CANCERS	\$200,000	\$200,000	04	100	\$200,000
Sarkar D	NIAAA	5R01AA011591-18	4/1/1998	4/30/2023	ALCOHOL AND HYPERPROLACTINEMIA	\$225,000	\$225,000	04	100	\$225,000
Sharma A	COG	CINJ Protocol #111506	9/30/2000	12/28/2099	COG AAML1331: PHASE III STUDY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA (APL) USING ARSENIC TRIOXIDE AND ALL-TRANS RETINOIC ACID	\$2,692	\$2,692	04	100	\$2,692
Sharma A	COG	CINJ Protocol #111706	9/30/2000	12/28/2099	CINJ PROTOCOL #111706	\$769	\$769	04	100	\$769

Sharma A	COG	CINJ Protocol #111707	9/30/2000	12/28/2009	COG AALL1621: A PHASE 2 STUDY OF INOTUZUMAB OZOGAMICIN (NSC# 772518, IND#133494) IN CHILDREN AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY CD22+ B-ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)	\$2,083	\$2,083	04	100	\$2,083
Shen Z	NCI	5P01CA250957-02	5/1/2021	4/30/2026	MECHANISMS OF THE BRCA-NETWORK IN TUMORIGENESIS AND THERAPEUTIC RESPONSE					
Shen Z Ganesan S	NCI	5P01CA250957-02 (9486)	5/1/2021	4/30/2026	MECHANISMS OF THE BRCA-NETWORK IN TUMORIGENESIS AND THERAPEUTIC RESPONSE: PROJECT 3: CHROMATIN MODIFIERS OF BRCA-RELATED DNA REPAIR PATHWAYS (SUBPROJECT 9486)	\$247,283	\$247,283	04	100	\$247,283
Steinberg M Heckman C Stepanov I (U. of Minnesota)	NCI	7R01CA260831-02	2/15/2022	1/31/2026	EVALUATING CIGARETTE RELIGHTING BEHAVIOR: PREVALENCE, CORRELATES, TOXICANT EXPOSURE, AND IMPLICATIONS FOR CESSATION	\$496,671	\$496,671	04	50	\$248,336
Suh N	NCI	1R03CA259650-01A1	4/11/2022	3/31/2024	A NOVEL STRATEGY TARGETING TP63 FOR BREAST CANCER PREVENTION	\$50,000	\$50,000	04	100	\$50,000
Toppmeyer D	ECOG	CINJ Protocol #010801	9/30/2000	12/28/2009	CINJ PROTOCOL #010801	\$1,000	\$1,000	04	100	\$1,000
Toppmeyer D	ECOG	CINJ Protocol #030704	9/30/2000	12/28/2009	CINJ PROTOCOL #030704	\$350	\$350	04	100	\$350
Toppmeyer D	ECOG	CINJ Protocol #031504	9/30/2000	12/28/2009	CINJ PROTOCOL #031504	\$3,904	\$3,904	04	100	\$3,904
Toppmeyer D	ECOG	CINJ Protocol #041803	1/22/1998	4/21/2009	CINJ PROTOCOL #041803	\$1,100	\$1,100	04	100	\$1,100
Zhang L	NCI	1R37CA277812-01	9/1/2022	8/31/2026	SCH: SCREENING AND CONFIRMATORY MACHINE LEARNING FOR EXPLAINABLE MODELING OF NON-CANCER DEATHS IN CANCER PATIENTS	\$183,651	\$183,651	04	100	\$183,651
Peer-Reviewed Research Subtotals						\$8,019,493	\$7,701,022			\$5,914,984